Michael Cloonan sold $728k of SION
President & CEO at Sionna Therapeutics, Inc.. 25,000 shares at an average of $29.11, traded Sep 26, 2025, filed Sep 30, 2025.
Score components
- +25RoleCEO
- +21Trade size$728k at market
- 0Share of holdings soldSold 4.4% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001704336-25-000004, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 26, 2025 | MOption exercise Common Stock10b5-1 | +17,207 | $6.11 | $105k | 564,550 | Sep 30, 2025 |
| Sep 26, 2025 | SOpen-market sale Common Stock10b5-1 | -17,207 | $28.85 | $496k | 547,343 | Sep 30, 2025 |
| Sep 29, 2025 | MOption exercise Common Stock10b5-1 | +7,793 | $6.11 | $48k | 555,136 | Sep 30, 2025 |
| Sep 29, 2025 | SOpen-market sale Common Stock10b5-1 | -7,793 | $29.70 | $231k | 547,343 | Sep 30, 2025 |
| Sep 26, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -17,207 | $0.00 | $0 | 185,935 | Sep 30, 2025 |
| Sep 29, 2025 | MOption exercise Non-Qualified Stock Option (right to buy)derivative10b5-1 | -7,793 | $0.00 | $0 | 178,142 | Sep 30, 2025 |
Related signals
Other insiders at Sionna Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 50Moderate | SIONsell Sionna Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $22M 3,448,811 shares | -50% | |
| 28Weak | Sionna Therapeutics, Inc. | Jennifer Fitzpatrick Chief Legal Officer | $237k 10,250 shares | -100% | |
| 35Weak | Sionna Therapeutics, Inc. | Elena Ridloff CFO & Head of Corp. Dev. | $240k 9,584 shares | -20% | |
| 25Weak | Sionna Therapeutics, Inc. | Michael Cloonan President & CEO | $624k 25,000 shares | -4% | |
| 46Moderate | Sionna Therapeutics, Inc. | Elena Ridloff CFO & Head of Corp. Dev. | $602k 23,416 shares | -33% | |
| 17Weak | Sionna Therapeutics, Inc. | Michael Cloonan President & CEO | $569k 25,000 shares | -4% | |
| 45Moderate | Sionna Therapeutics, Inc. | Elena Ridloff CFO & Head of Corp. Dev. | $1.1M 52,000 shares | -42% | |
| 34Weak | SIONbuy Sionna Therapeutics, Inc. | Tpg Gp A, LLC owner | $950k 60,000 shares | +1% | |
| 53Moderate | Sionna Therapeutics, Inc. | Tpg Gp A, LLC owner | $20M 1,125,000 shares | +20% | |
| 50Moderate | Sionna Therapeutics, Inc. | Atlas Venture Fund XI, L.P. owner | $1.1M 60,000 shares | +8% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.